| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-03-23 | Novosanis (Belgium) MDxHealth (Belgium) | UrNCollect™ | distribution | Technology - Services - Diagnostic | Distribution agreement | |
| 2017-03-23 | Retrophin (USA - CA) | nomination | Rare diseases | Nomination | ||
| 2017-03-23 | Pierre Fabre Laboratories (France) Setubio (France) | Nature Open Library program | collaboration | Technology - Services | Collaboration agreement | |
| 2017-03-23 | Erytech Pharma (France) Fox Chase Cancer Center (USA - PA) | erymethionase program | homocystinuria | research | Rare diseases - Genetic diseases - Metabolic diseases | Research agreement |
| 2017-03-22 | Galapagos (Belgium) AbbVie (USA - IL) | novel potentiator and combination therapies in cystic fibrosis | cystic fibrosis | R&D development commercialisation | Rare diseases - Genetic diseases | Milestone |
| 2017-03-22 | Atlantic Healthcare (UK) | chairman of the board of directors | resignation | Inflammatory diseases - Gastrointestinal diseases | Resignation | |
| 2017-03-22 | Avrobio (USA - MA) Dr. Stefan Karlsson at Lund University (Sweden) | investigational gene therapy to treat Gaucher disease | Gaucher disease | licensing | Rare diseases - Genetic diseases | Licensing agreement |
| 2017-03-21 | Partners test now | Compound: | Disease: | Type of agreement: | Therapeutic_area:asdsadas | Plant acquisition |
| 2017-03-21 | MDxHealth (Belgium) Lab21 (UK), part of the Novacyt Group (France) | SelectMDx™ for Prostate Cancer test | prostate cancer | distribution | Cancer - Oncology - Diagnostic | Distribution agreement |
| 2017-03-21 | Argen-X (Belgium - The Netherlands) Broteio Pharma (The Netherlands) | antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. | autoimmune haemolytic anaemia (AIHA), antibody mediated rejection (AMR) following organ transplantation. | development | Autoimmune diseases | Development agreement |
| 2017-03-21 | Piqur Therapeutics (Switzerland) | nomination | Nomination | |||
| 2017-03-21 | X-Chem (USA - MA) Ono Pharmaceutical (Japan) | small molecules | development commercialisation | Cancer - Oncology | Development agreement | |
| 2017-03-21 | Pierre Fabre (France) H-Immune (France) | fully human monoclonal antibody candidates | research development | Cancer - Oncology | R&D agreement | |
| 2017-03-21 | Stimunity (France) Institut Curie (France) Inserm (France) | VLP-cGAMP technology | licensing R&D | Cancer - Oncology | Licensing agreement | |
| 2017-03-21 | Oramed Pharmaceuticals (Israel) | nomination | Metabolic diseases | Nomination | ||
| 2017-03-20 | Arix Bioscience (UK) the Lead Discovery Center (Germany) Max Planck Innovation (Germany) the University of Leeds (UK) | antagonists of a novel target for a variety of metabolic indications | Cardiovascular diseases - Metabolic diseases | Development agreement | ||
| 2017-03-20 | Loxo Oncology (USA - CT) Ventana Medical Systems,(USA), a member of the Roche Group (Switzerland) | pan-TRK immunohistochemistry (IHC) test as a companion diagnostic to identify patients across tumor types suitable for treatment with larotrectinib | development, commercialisation | Cancer - Oncology - Diagnostic | Development agreement | |
| 2017-03-20 | Arena Pharmaceuticals (USA - CA) | nomination | Nomination | |||
| 2017-03-20 | Bluebird bio (USA - MA) | Chief Technology and Manufacturing Officer, Senior Vice President, Corporate Development and Strategy. | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-03-20 | BMS (USA - NY) CytomX Therapeutics (USA - CA) | probodies for up to six oncology targets including CTLA-4 | licensing development | Cancer - Oncology | Development agreement |
